Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02458495 · ClinicalTrials.gov registry record · NA

The Diabetes Medication Adherence Promotion Intervention Trial

A NA study of Diabetes Mellitus, Type 2, sponsored by Vanderbilt University.

Completed
Registry status
NA
Development phase
151
Enrollment target
1
Study location

NCT02458495: Completed NA study of Diabetes Mellitus, Type 2, sponsored by Vanderbilt University.

NCT02458495 is a NA study of Diabetes Mellitus, Type 2 that has completed, run by Vanderbilt University. The registered enrollment target is 151 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02458495, a NA study of Diabetes Mellitus, Type 2, has completed, sponsored by Vanderbilt University.

COMPLETED
Registry status
NA
Development phase
151 participants
Enrollment target
1
Study location

Study Summary

A significant percentage of persons with diabetes fail to properly take their prescribed oral hypoglycemic agents (OHA) and insulin. Non-adherence to medications among diabetes patients is associated with poor health outcomes including suboptimal glycemic control, diabetes-related complications, elevated health costs and increased risk of hospitalization and mortality. Given the substantial impact of non-compliance on the health of patients, prior studies have sought to draw links between medication adherence and patient factors. Research shows that web-based interventions that support patients' medication-related knowledge, motivation and skills effectively improve compliance. The purpose of this study is to evaluate the impact of a patient web portal (PWP)-delivered medication adherence promotion intervention on medication adherence and glycemic control among patients with type 2 diabetes (T2DM). The intervention aims to (1) increase self-reported adherence to glucose lowering agents (GLAs) and (2) improve diabetes health outcomes (decreased HbA1c) by increasing patients' medication adherence-related knowledge, motivation and skills. This research will greatly enhance the investigators' understanding of medicine compliance and the factors that effectively improve adherence among high-risk patients with diabetes. Knowledge gained from this work may inform future internet-based patient portals that support disease management and medication adherence more broadly.

Primary Outcome

Change in participant's HbA1c level from study onset to study conslusion

Conditions Studied

Interventions

  • BEHAVIORAL Diabetes MAP Intervention

Study Locations (1)

Tennessee

  • Vanderbilt University Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 151 participants
Start Date 2015-08
Est. Completion 2016-09
Phase NA
Vanderbilt University

430 total trials

What the finished NCT02458495 record still lists

NCT02458495 is an interventional study that assigns participants to a tested intervention. The registered 151 participants enrollment target is mid-sized for trials with a published cap, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which Diabetes MAP Intervention is the first listed.

NCT02458495 reports a single indexed study location in Tennessee.

Frequently Asked Questions

What is clinical trial NCT02458495 about?

NCT02458495 is a clinical study titled "The Diabetes Medication Adherence Promotion Intervention Trial". A significant percentage of persons with diabetes fail to properly take their prescribed oral hypoglycemic agents (OHA) and insulin. Non-adherence to medications among diabetes patients is associated with poor health outcomes including suboptimal glycemic control, diabetes-related complications, ele...

What is the current status of trial NCT02458495?

This trial is currently completed. It is a NA study. The enrollment target is 151 participants. The study started on 2015-08. Estimated completion is 2016-09.

What conditions does trial NCT02458495 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.

What interventions are being tested in trial NCT02458495?

The interventions under investigation include: Diabetes MAP Intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT02458495?

This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02458495 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02458495's enrollment target sits among peer trials

151 172nd of 348 higher than 177 of 348 other Diabetes Mellitus, Type 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01409161 · 151 participants · Phase 2

    Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

  • NCT04245397 · 151 participants · Phase 1

    Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

  • NCT05761223 · 151 participants · Phase 1

    A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849

  • NCT07195656 · 151 participants · NA

    Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02458495, the US trial registry maintained by the National Library of Medicine. NCT02458495 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.